Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CTT Pharmaceutical HoldingsCTTH Equity-to-Asset is 0.39 as of Jun. 2026, which is 20% below its 10-year median of 0.49. The stock has 1 warning sign investors should review. Among 1,009 Drug Manufacturers companies, CTT Pharmaceutical Holdings ranks worse than 77.01% on this metric.
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
CTT Pharmaceutical Holdings Equity-to-Asset Related Terms
CTT Pharmaceutical Holdings Equity-to-Asset Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CTTH vs PRFX, UPC, AKAN: Equity-to-Asset Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, CTT Pharmaceutical Holdings's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CTT Pharmaceutical Holdings Equity-to-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, CTT Pharmaceutical Holdings's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where CTT Pharmaceutical Holdings's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
CTT Pharmaceutical Holdings's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CTT Pharmaceutical Holdings (CTTH) has a Equity-to-Asset of 0.39 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on CTT Pharmaceutical Holdings and its competitors. This is 20% below median its historical median of 0.49. According to the industry distribution chart, CTT Pharmaceutical Holdings ranks #777 out of 1009 companies in the Drug Manufacturers industry, placing it in the top 77%.
Is CTT Pharmaceutical Holdings' Equity-to-Asset too high?
CTT Pharmaceutical Holdings' current Equity-to-Asset of 0.39 is 20% below median its 10-year median of 0.49. The Drug Manufacturers industry median Equity-to-Asset is 0.60. CTT Pharmaceutical Holdings' value of 0.39 is 35% below this industry median. Based on the distribution chart, CTT Pharmaceutical Holdings ranks #777 out of 1009 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does CTT Pharmaceutical Holdings' Equity-to-Asset compare to PRFX and UPC?
According to the Drug Manufacturers industry distribution chart, CTT Pharmaceutical Holdings ranks #777 out of 1009 companies for Equity-to-Asset. This places CTT Pharmaceutical Holdings in the lower half of its industry. The industry median Equity-to-Asset is 0.60. CTT Pharmaceutical Holdings' value of 0.39 is 35% below this benchmark. While the company's 10-year median is 0.49 vs. the industry median of 0.60, CTT Pharmaceutical Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Drug Manufacturers company?
The median Equity-to-Asset among Drug Manufacturers companies is 0.60, based on 1,009 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CTT Pharmaceutical Holdings's current Equity-to-Asset of 0.39 is 35% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on CTT Pharmaceutical Holdings and its competitors. For the Drug Manufacturers industry, the median Equity-to-Asset is 0.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CTT Pharmaceutical Holdings's current Equity-to-Asset is 0.39, which is 20% below median its own 10-year median of 0.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CTT Pharmaceutical Holdings stock overvalued right now?
CTT Pharmaceutical Holdings (CTTH) has a current Equity-to-Asset of 0.39. The current Equity-to-Asset is 0.39, which is 20% below median its 10-year median of 0.49 and 35% below the Drug Manufacturers industry median of 0.60. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For CTT Pharmaceutical Holdings (CTTH), the current Equity-to-Asset is 0.39 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
CTT Pharmaceutical Holdings Inc specializes in drug delivery systems technology within the pharmaceutical industry. Its focus is on fast-dissolving drug delivery systems through the development of oral delivery thin wafers. The company's technology platform includes the development of oral delivery thin wafers to deliver treatment as an alternative to smoking and ingestion. This technology platform target both the human and veterinarian(pet) markets for treatment of many diseases. The Company believes that its technology will be one of the first to gain use in majorly markets such as pain management and smoking cessation. The Oral Thin Film formulation is protected by patents in the USA, Canada, Europe and many other countries across the world.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CTTH has been successfully added to your 
